Navigation Links
New Clinical Data for Cytogen's Quadramet and Prostacint to be,Reported at Upcoming Major Medical Meetings

PRINCETON, N.J.--(BUSINESS WIRE)--Mar 26, 2007 - Cytogen Corporation (NASDAQ: CYTO) today announced that five abstracts will be presented or published at upcoming major medical meetings. The data will include various Phase 1 clinical results for QUADRAMET(R) (samarium Sm-153 lexidronam injection) in combination settings for the treatment of metastatic bone disease arising from prostate cancer and multiple myeloma, as well as data from a study evaluating the outcomes of prostate cancer patients based on the findings of PROSTASCINT(R) (capromab pendetide) imaging. These presentations underscore Cytogen's strategy to maximize the market potential of its approved products through data-driven initiatives.

New data from three separate Phase 1 studies of QUADRAMET in combination with docetaxel (Taxotere(R), Sanofi-Aventis) in patients with hormone-refractory prostate cancer have been accepted for publication and/or presentation at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place June 1-5, 2007, in Chicago, Illinois. The primary objective of each of these Phase 1 studies is to determine the safety and tolerability of the combination regimens utilizing a variety of doses and dosing regimens.

Additionally, new and complete data from a Phase 1 study evaluating QUADRAMET in combination with bortezomib (Velcade(R), Millennium Pharmaceuticals, Inc.) in patients with relapsed multiple myeloma will be presented in an oral presentation at the XIth International Myeloma Workshop taking place June 25-30, 2007 in Greece. The primary objective of the Phase 1 study was to determine the safety and tolerability of the combination regimen. As a secondary objective, the study also assessed response rates.

Today, Cytogen also reported that new data from an outcomes study in prostate cancer patients whose PROSTASCINT images showed uptake in the central abdomen as compared to those with
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:2/27/2015)... -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) ... net operating loss (NOL) guidance and its cash guidance ... significantly improved financial results were due in large part ... Company received from its partners.  Isis, pro forma NOL ... improvement over its 2013 NOL of $40.2 million. On ...
(Date:2/27/2015)... Mass. , Feb. 27, 2015  Boston Scientific ... participate in the Barclays 2015 Annual Healthcare Conference on ... Dan Brennan , executive vice president ... vice president, Investor Relations, will participate in a 25-minute ... host analyst at approximately 1:05 p.m. ET. Following a ...
(Date:2/27/2015)... , Feb. 27, 2015  In recognition of ... commitment to the global bleeding disorders community, CSL ... million international units (IUs) of protein therapies to the ... not-for- profit organization which has worked to improve the ... disorders. The donation supports the WFH,s Global Alliance for ...
Breaking Medicine Technology:Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 2CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 3
... WASHINGTON, Oct. 22 Today, the American,Society of ... Oncology,(ASCO) have released an updated joint guideline on ... drugs that stimulate,the bone marrow to produce more ... goal of these guidelines is to inform clinicians ...
... leading,provider of quality control standards for clinical diagnostic ... their OptiQuant,HIV-1 Quantification Panel to be the first ... product is for Research Use Only, not for ... OptiMatrix, allows the OptiQuant HIV-1 panel to,most closely ...
Cached Medicine Technology:ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients 2ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients 3AcroMetrix Releases New OptiQuant(R) HIV-1 Quantification Panel 2
(Date:2/28/2015)... 2015 The MCA Youth Empowerment Conference ... one platform and gears towards the goal for a ... of group talks in smaller groups will be held ... Personal Development, Leadership, Entrepreneurship, Healthcare, Social and Volunteerism, Women ... Malaysian youths. , Young adults aged between ...
(Date:2/28/2015)... Gerald “Solutionman” Haman surveyed over 10,000 people to discover ... “The #1 block was lack of time and ... who created the Thinkubator Innovation Studio in Chicago. ... did not have enough time for innovative thinking and ... , Solutionman’s monthly “Accelerating Innovation Training” workshops address the ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 March—also ... good time to remind ourselves and others that ... say Atlantic NeuroSurgical Specialists (ANS). , Concussions are ... account for 75% of TBIs. There are 1.6-3.8 ... may sound benign, but it is a brain ...
(Date:2/28/2015)... 28, 2015 A study out of ... gene therapy procedure for the treatment of a hereditary ... Authored by Dr. Robert MacLaren, professor of ... the Lancet Medical Journal on January 16, 2014 , ... rare genetic disorder that mostly affects men and leads ...
(Date:2/28/2015)... 28, 2015 National Sales ... sales, marketing and supply chain management for consumer ... is bringing its award winning solutions for thinning-damaged ... products are specifically created to combat thinning-damaged hair. ... is committed to marrying science with nature to ...
Breaking Medicine News(10 mins):Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 3Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3
... a five-month-old baby boy will undergo a liver transplant at the ... forward.// The surgery is expected to take as long as 10 ... be used. ,Lennox developed chronic liver problems and ... to be completely blocked, and a transplant appeared to be the ...
... that go the wrong way to cause cancer were to form ... first page.// ,The U.S. government has set out to ... makeup of cancer, with the idea of speeding the discovery of ... luck. ,Dr. Francis Collins, the National Institutes of Health's ...
... There has been a considerable fall in the donations towards ... the United Nations (UN). The December 2005 contributions were not ... // ,Jan Vandemoortele, the UN Resident Coordinator has appealed ... been pledged by them. A special envoy will be appointed ...
... bird flu, increasing the risk of human infection in parts ... from a 35-year-old man who died in Jakarta last month ... World Health Organization reference laboratory, Health Ministry officials said today. ... bird flu in the world's fourth most-populous nation to 9. ...
... new pathway with regard to the progression of chronic myelogenous ... They have also found out that an extract from the ... used for suppressing the process. As many as 4,600 people ... year, and the findings may contribute towards their treatment options. ...
... been lots of talk about the health benefits of nuts but ... pack a nutritional wallop — at least when eaten in moderation.// ... for most nuts to say that there is good evidence they ... study it has been found that a diet rich in fruits ...
Cached Medicine News:Health News:U.S. launching cancer gene-mapping pilot 2Health News:Indonesia Has Ninth Bird-Flu Death as Risk Mounts 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: